Summit Therapeutics Inc. Payments to Acquire Short-term Investments
Summit Therapeutics Inc. (SMMT) reported Payments to Acquire Short-term Investments of $402.28 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireShortTermInvestments · last filed 2026-07-23
- Summit Therapeutics Inc. payments to acquire short-term investments for the quarter ending 2026-06-30 was $224.99M.
- Summit Therapeutics Inc. payments to acquire short-term investments for the quarter ending 2026-03-31 was $177.29M.
- Summit Therapeutics Inc. payments to acquire short-term investments for the quarter ending 2025-12-31 was $484.99M, a 224.44% increase year-over-year.
- Summit Therapeutics Inc. payments to acquire short-term investments for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Summit Therapeutics Inc. payments to acquire short-term investments for fiscal 2025 was $484.99M, a 28.68% decline from fiscal 2024.
- Summit Therapeutics Inc. payments to acquire short-term investments for fiscal 2024 was $680.03M, a 111.83% increase from fiscal 2023.
- Summit Therapeutics Inc. payments to acquire short-term investments for fiscal 2023 was $321.02M.
- Summit Therapeutics Inc. payments to acquire short-term investments for fiscal 2022 was $0.00.
| Period end | Payments to Acquire Short-term Investments 3 month | Payments to Acquire Short-term Investments 6 month | Payments to Acquire Short-term Investments 9 month | Payments to Acquire Short-term Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $224.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-23 | $402.28M 10-Q · filed 2026-07-23 | $887.27M derived: sum of 3 quarters · filed 2026-07-23 | $887.27M derived: sum of 4 quarters · filed 2026-07-23 |
| 2026-03-31 | $177.29M 10-Q · filed 2026-04-30 | $662.28M derived: sum of 2 quarters · filed 2026-04-30 | $662.28M derived: sum of 3 quarters · filed 2026-04-30 | $662.28M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-12-31 | $484.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $484.99M derived: sum of 2 quarters · filed 2026-02-23 | $484.99M derived: sum of 3 quarters · filed 2026-07-23 | $484.99M 10-K · filed 2026-02-23 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-20 | $0.00 derived: sum of 2 quarters · filed 2026-07-23 | $0.00 10-Q · filed 2025-10-20 | $149.49M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-23 | $0.00 10-Q · filed 2026-07-23 | $149.49M derived: sum of 3 quarters · filed 2026-07-23 | $317.04M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-03-31 | $0.00 10-Q · filed 2026-04-30 | $149.49M derived: sum of 2 quarters · filed 2026-04-30 | $317.04M derived: sum of 3 quarters · filed 2026-04-30 | $587.05M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $149.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $317.04M derived: sum of 2 quarters · filed 2026-02-23 | $587.05M derived: sum of 3 quarters · filed 2026-02-23 | $680.03M 10-K · filed 2026-02-23 |
| 2024-09-30 | $167.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-20 | $437.56M derived: sum of 2 quarters · filed 2025-10-20 | $530.54M 10-Q · filed 2025-10-20 | $530.54M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $270.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $363.00M 10-Q · filed 2025-08-11 | $362.99M derived: sum of 3 quarters · filed 2026-02-23 | $475.85M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $92.98M 10-Q · filed 2025-05-01 | $92.98M derived: sum of 2 quarters · filed 2026-02-23 | $205.84M derived: sum of 3 quarters · filed 2026-02-23 | $244.01M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $112.86M derived: sum of 2 quarters · filed 2026-02-23 | $151.03M derived: sum of 3 quarters · filed 2026-02-23 | $321.02M 10-K · filed 2026-02-23 |
| 2023-09-30 | $112.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $151.03M derived: sum of 2 quarters · filed 2024-10-30 | $321.02M 10-Q · filed 2024-10-30 | $321.02M derived: sum of 4 quarters · filed 2025-02-24 |
| 2023-06-30 | $38.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $208.16M 10-Q · filed 2024-08-06 | $208.16M derived: sum of 3 quarters · filed 2025-02-24 | $208.16M derived: sum of 4 quarters · filed 2025-02-24 |
| 2023-03-31 | $170.00M 10-Q · filed 2024-05-01 | $170.00M derived: sum of 2 quarters · filed 2025-02-24 | $170.00M derived: sum of 3 quarters · filed 2025-02-24 | $170.00M derived: sum of 4 quarters · filed 2025-02-24 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | $0.00 derived: sum of 2 quarters · filed 2025-02-24 | $0.00 derived: sum of 3 quarters · filed 2025-02-24 | $0.00 10-K · filed 2025-02-24 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $0.00 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |